Observed Signal · Jul 15, 2026 · corporate_event · Source: SEC API · Impact: 3.8/5
financials Market: 8-K Financial Filing Analysis for Johnson & Johnson
Johnson & Johnson filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on July 15, 2026, announcing its financial results for the fiscal second quarter ended June 28, 2026. The filing furnishes the official quarterly press release alongside unaudited comparative supplementary sales data and condensed consolidated statements of earnings for both the second quarter and the first six months of the fiscal year.
Quarterly earnings releases under Item 2.02 are essential market events that communicate official top-line sales and bottom-line earnings trends for global healthcare and pharmaceutical bellwethers.
Key Takeaways & Evidence Grounding
- Johnson & Johnson released its sales and earnings report for the second quarter ended June 28, 2026, via Item 2.02.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings).
- The report was formally signed on July 15, 2026, by Controller and Principal Accounting Officer Robert J. Decker, Jr.
Connected Companies & Entities
1 Entity mappedTrack Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.